LATS1/2 Kinases Trigger Self-renewal of Cancer Stem Cells in Aggressive Oral Cancer
Overview
Authors
Affiliations
Cancer stem cells (CSCs), which play important roles in tumor initiation and progression, are resistant to many types of therapies. However, the regulatory mechanisms underlying CSC-specific properties, including self-renewal, are poorly understood. Here, we found that LATS1/2, the core Hippo pathway-kinases, were highly expressed in the oral squamous cell carcinoma line SAS, which exhibits high capacity of CSCs, and that depletion of these kinases prevented SAS cells from forming spheres under serum-free conditions. Detailed examination of the expression and activation of LATS kinases and related proteins over a time course of sphere formation revealed that LATS1/2 were more highly expressed and markedly activated before initiation of self-renewal. Moreover, TAZ, SNAIL, CHK1/2, and Aurora-A were expressed in hierarchical, oscillating patterns during sphere formation, suggesting that the process consists of four sequential steps. Our results indicate that LATS1/2 trigger self-renewal of CSCs by regulating the Hippo pathway, the EMT, and cell division.
Synthesis and use of thermoplastic polymers for tissue engineering purposes.
Bianchi E, Ruggeri M, Vigani B, Aguzzi C, Rossi S, Sandri G Int J Pharm X. 2025; 9():100313.
PMID: 39807177 PMC: 11729033. DOI: 10.1016/j.ijpx.2024.100313.
Putra A, Andrijono , Winarto H, Prijanti A, Rachmadi L, Pakasi T Int J Mol Sci. 2024; 25(19).
PMID: 39408872 PMC: 11477450. DOI: 10.3390/ijms251910545.
Sakurai K, Nagai A, Ando T, Sakai Y, Ideta Y, Hayashi Y Cancer Genomics Proteomics. 2022; 20(1):64-74.
PMID: 36581338 PMC: 9806669. DOI: 10.21873/cgp.20365.
LATS kinases and SLUG regulate the transition to advanced stage in aggressive oral cancer cells.
Fujibayashi E, Mukai S, Torigata K, Ando Y, Uchihashi T, Nozaki M Sci Rep. 2022; 12(1):12363.
PMID: 35859006 PMC: 9300623. DOI: 10.1038/s41598-022-16667-5.
The deadly cross-talk between Hippo pathway and epithelial-mesenchymal transition (EMT) in cancer.
Akrida I, Bravou V, Papadaki H Mol Biol Rep. 2022; 49(10):10065-10076.
PMID: 35604626 DOI: 10.1007/s11033-022-07590-z.